SUVEN LIFE SCIENCES Financial Statement Analysis
|
||
|
The Revenues of SUVEN LIFE SCIENCES have increased by 6.90% YoY .
The Earnings Per Share (EPS) of SUVEN LIFE SCIENCES has decreased by Negative YoY. |
||
SUVEN LIFE SCIENCES Last 5 Annual Financial Results
[BOM: 530239|NSE : SUVEN]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹7.12 Cr | ₹6.66 Cr | ₹12 Cr | ₹14 Cr | ₹12 Cr |
| Expenses | ₹291 Cr | ₹172 Cr | ₹140 Cr | ₹139 Cr | ₹134 Cr |
| Operating Profit (Excl OI) | ₹-284 Cr | ₹-166 Cr | ₹-128 Cr | ₹-126 Cr | ₹-122 Cr |
| Other Income | ₹14 Cr | ₹11 Cr | ₹21 Cr | ₹8.45 Cr | ₹1.60 Cr |
| Interest | ₹0.31 Cr | ₹0.17 Cr | ₹0.30 Cr | ₹0.41 Cr | ₹0.67 Cr |
| Depreciation | ₹5.61 Cr | ₹5.82 Cr | ₹6.50 Cr | ₹6.54 Cr | ₹4.39 Cr |
| Profit Before Tax | ₹-276 Cr | ₹-161 Cr | ₹-106 Cr | ₹-118 Cr | ₹-122 Cr |
| Profit After Tax | ₹-276 Cr | ₹-161 Cr | ₹-105 Cr | ₹-118 Cr | ₹-122 Cr |
| Consolidated Net Profit | ₹-276 Cr | ₹-161 Cr | ₹-105 Cr | ₹-118 Cr | ₹-122 Cr |
| Earnings Per Share (Rs) | ₹-10.48 | ₹-7.37 | ₹-4.82 | ₹-5.42 | ₹-8.39 |
| PAT Margin (%) | -3,884.13 | -2,415.11 | -898.63 | -873.52 | -1,029.99 |
| ROE(%) | -101.80 | -84.88 | -32.56 | -50.17 | -145.90 |
| ROCE(%) | -78.71 | -84.51 | -32.78 | -49.94 | -117.81 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Key Financials |
||
| Market Cap | : | ₹ 9,416.2 Cr |
| Revenue (TTM) | : | ₹ 8.8 Cr |
| Net Profit(TTM) | : | ₹ -352.4 Cr |
| EPS (TTM) | : | ₹ -12.5 |
| P/E (TTM) | : | - |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SUVEN LIFE SCIENCES | -2% | 2% | 36.8% |
| SUN PHARMACEUTICAL INDUSTRIES | -3% | -2.6% | 21.3% |
| DIVIS LABORATORIES | -0.5% | 17% | 43.8% |
| TORRENT PHARMACEUTICALS | 0.6% | 2.7% | 35.5% |
| CIPLA | -2.2% | 0.8% | -2.4% |
| DR REDDYS LABORATORIES | -1.1% | -1.6% | -0.8% |
| MANKIND PHARMA | -1% | -3.7% | -1.9% |
| LUPIN | -0.8% | -7.5% | 16.6% |
| ZYDUS LIFESCIENCES | -4.1% | -0.9% | 21.9% |
SUVEN LIFE SCIENCES Revenues
[BOM: 530239|NSE : SUVEN]
| Y-o-Y | 6.90 % |
| 5 Yr CAGR | -11.96 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹7.12 Cr | 6.90 | |
| Mar2025 | ₹6.66 Cr | -43.08 | |
| Mar2024 | ₹12 Cr | -13.63 | |
| Mar2023 | ₹14 Cr | 14.31 | |
| Mar2022 | ₹12 Cr | - | |
SUVEN LIFE SCIENCES Operating Profit
[BOM: 530239|NSE : SUVEN]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹-284 Cr | Negative | |
| Mar2025 | ₹-166 Cr | Negative | |
| Mar2024 | ₹-128 Cr | Negative | |
| Mar2023 | ₹-126 Cr | Negative | |
| Mar2022 | ₹-122 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | -3996.56% | Negative | |
| Mar2025 | -2488.79% | Negative | |
| Mar2024 | -1093.52% | Negative | |
| Mar2023 | -928.89% | Negative | |
| Mar2022 | -1032.16% | - | |
SUVEN LIFE SCIENCES Profit After Tax
[BOM: 530239|NSE : SUVEN]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹-276 Cr | Negative | |
| Mar2025 | ₹-161 Cr | Negative | |
| Mar2024 | ₹-105 Cr | Negative | |
| Mar2023 | ₹-118 Cr | Negative | |
| Mar2022 | ₹-122 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | -3884.13 % | Negative | |
| Mar2025 | -2415.11 % | Negative | |
| Mar2024 | -898.63 % | Negative | |
| Mar2023 | -873.52 % | Negative | |
| Mar2022 | -1029.99 % | - | |
SUVEN LIFE SCIENCES Earnings Per Share (EPS)
[BOM: 530239|NSE : SUVEN]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹-10 | Negative | |
| Mar2025 | ₹-7.37 | Negative | |
| Mar2024 | ₹-4.82 | Negative | |
| Mar2023 | ₹-5.42 | Negative | |
| Mar2022 | ₹-8.39 | - | |
SUVEN LIFE SCIENCES Return on Capital Employed (ROCE)
[BOM: 530239|NSE : SUVEN]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | -78.71% | Negative | |
| Mar2025 | -84.51% | Negative | |
| Mar2024 | -32.78% | Negative | |
| Mar2023 | -49.94% | Negative | |
| Mar2022 | -117.81% | - | |
SUVEN LIFE SCIENCES Share Price vs Sensex
| Current Share Price | : | ₹333.2 |
| Current MarketCap | : | ₹ 9,416.2 Cr |
| Updated EOD on | : | Aug 17,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUVEN LIFE SCIENCES | -2% |
2% |
36.8% |
| SENSEX | -1% |
0.7% |
-3.6% |
SUVEN LIFE SCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 1000 | -0.5% | 1.7% | 4.2% |
| BSE HEALTHCARE | -1% | 0.5% | 16.1% |
No NSE index found
You may also like the below Video Courses
FAQ about SUVEN LIFE SCIENCES Financials
How the annual revenues of SUVEN LIFE SCIENCES have changed ?
The Revenues of SUVEN LIFE SCIENCES have increased by 6.90% YoY .
How the Earnings per Share (EPS) of SUVEN LIFE SCIENCES have changed?
The Earnings Per Share (EPS) of SUVEN LIFE SCIENCES has decreased by Negative YoY .
Check out Intrinsic Value of Peers of SUVEN LIFE SCIENCES
Compare Stock Analytics of Peers of SUVEN LIFE SCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
